In the present study, premenopausal patients with operable BC receiving 5 years of adjuvant tamoxifen without subsequent use of aromatase inhibitor had an inferior BCSS if serum concentrations of Z‐4OHtam were ≤ 3.26 nm. This evidence concerns the gene CYP19A1 and breast cancer.